SYRESpyre Therapeutics, Inc.

1. Oct 7, 2026On October 5, 2026, Spyre Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated, as the representatives of the underwriters named therein (the …Material agreement entered · Form 8-K
2. Sep 8, 2026On September 8, 2026, the Company announced positive 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY003, an anti-IL-23 being investigated for the treatment of moderately-to-severely active UC. SPY003 SKYLINE Part A Induction Topline Results Efficacy: POC Established Across All Three …Regulation FD disclosure · Form 8-K
3. Aug 25, 2026On August 25, 2026, the Company announced topline results from the RA sub-study of the Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases.Regulation FD disclosure · Form 8-K
4. Aug 4, 2026Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
5. Jun 15, 2026On June 15, 2026, the Company announced positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY002 for the treatment of moderately-to-severely active UC. SPY002 SKYLINE Part A Induction Topline Results Initial 12-week findings from SKYLINE Part A demonstrated that SPY002 met all …Regulation FD disclosure · Form 8-K
6. Jun 1, 2026On May 29, 2026, the Company entered into the First Amendment to Amended and Restated License Agreement (the "Amendment"), amending the Amended and Restated License Agreement dated as of February 24, 2025 (as amended, the "SPY003 License Agreement"), by and between the Company and Paragon Therapeutics, Inc. ("Paragon")Other event · Form 8-K
7. May 5, 2026Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
8. Apr 16, 2026On April 14, 2026, Spyre Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC, as the representatives of the underwriters named therein (the “Underwriters”), relating to …Material agreement entered · Form 8-K
9. Apr 13, 2026Effective April 13, 2026, the Company suspended and terminated the prospectus (the “ATM Prospectus”) relating to the sale of its common stock, $0.0001 par value per share (the “Common Stock”) in an “at-the-market” offering pursuant to the terms of the Sales Agreement, dated, September 6, 2024, by and between the …Earnings release · Form 8-K
10. Apr 13, 2026On April 13, 2026, the Company announced positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY001 for the treatment of moderate-to-severely active UC. Additionally, the Company announced that recruitment for Part A of the SKYLINE Trial is now closed and enrollment is open for …Regulation FD disclosure · Form 8-K
11. Feb 19, 2026Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.